Background Level 1 evidence from randomised controlled studies in thyroid cancer
management is generally lacking. Therefore, the published US [

UK thyroid cancer survival figures are some of the worst in Europe. The 2002 British Thyroid
Association (BTA) guidelines aimed to address this and recommended slightly more …

The treatment of thyroid cancer remains controversial because of its relative rarity, long
natural history with generally good outcome, and lack of randomised trials. However …

This is the second edition of an outstanding textbook edited by Leonard Wartofsky and
Douglas Van Nostrand. The editors are to be congratulated on bringing together a …

This chapter has reviewed the UK guidelines for the management of thyroid cancer and
made reference to other available guidelines. The objective for clinicians involved in treating …

THIS ISSUE OF THYROID sees the publication by the American Thyroid Association
Taskforce of updated guidelines for the management of patients with thyroid nodules and …

This is the second review article on thyroid cancer dealing with the common differentiated
types that comprise 90% of thyroid cancers. Despite clinical management guidelines offered …

Thyroid cancer is uncommon with an estimated lifetime risk of 0.8% for women and 0.3% for
men. The incidence appears to be increasing by 4% per year and is currently the eighth …

Petros Perros, on behalf of the Thyroid Cancer Guidelines Update Group steadily
accumulating, therefore the publication of the second edition of the BTA/RCP guidelines for …

This ESMO Clinical Practice Guideline provides updated state-of-the-art recommendations
on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a …